Third quarter revenue of $21.2 million, an increase of 32% compared to prior year period
Gross margin of 73%, an increase of 150 basis points from the prior year period
Positive net income of $0.7 million compared to a net loss of ($3.5) million in prior year period
OXFORD, United Kingdom and MARLBOROUGH, Mass., November 5, 2019 (GLOBE NEWSWIRE) –Oxford Immunotec Global PLC (Nasdaq: OXFD), or the Company, a global, high-growth diagnostics company, today announced third quarter 2019 financial results.
“The third quarter represents another quarter of strong revenue growth, and improving profitability” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “The Company continues to see the global tuberculosis market expanding and we are investing in both commercial resources and research and development to capitalize on this opportunity.”
By revenue type, total revenues were, in millions: Three Months Ended September 30
By geography, total revenues were, in millions: Three Months Ended September 30
|2019||2018||As Reported (1) Constant Currency (1)||Percent Change|
|Europe & ROW||$2.7||$2.3||19%||24%|
(1) Oxford Immunotec completed its sale of the Company’s U.S. laboratory services business on November 6, 2018. As such, Total Revenue, Product Revenue, and United States Revenue for the three months ended September 30, 2019 and September 30, 2018 are not fully comparable. Total Revenue, Product Revenue, and United States Revenue for the three months ended September 30, 2018 include sales to our former U.S. laboratory services business at our intercompany transfer price that were formerly eliminated in consolidation. Total Revenue, Product Revenue, and United States Revenue for the three months ended September 30, 2019 include revenue from T-SPOT®.TB test kits and related accessories sold to Quest Diagnostics under the terms of a long-term supply agreement.
(2) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure “constant currency basis” in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.
Third Quarter 2019 Financial Results
Revenue for the third quarter of 2019 was $21.2 million, representing a 32% increase from third quarter 2018 revenue of $16.1 million. On a constant currency basis, revenue increased 31% versus the prior year period.
2019 third quarter product revenue was $20.1 million, representing a 33% increase from product revenue of $15.1 million in the third quarter of 2018. The increase was primarily a result of growth in the Asia Pacific region, particularly a normalizing of ordering patterns in Japan after a slow start to 2019. Service revenue for the third quarter of 2019 was $1.1 million, representing a 16% increase from third quarter 2018 service revenue of $1.0 million. The increase in service revenue reflected growth in tuberculosis testing volumes in our U.K. service laboratory.
United States revenue was $5.7 million in the third quarter of 2019, representing a 99% increase from revenue of $2.9 million in the prior year period. The growth was due to increased tuberculosis testing volumes and a higher selling price, compared to 2018 sales to the U.S. laboratory services business at our intercompany transfer price that were formerly eliminated in consolidation. On a pro forma basis, U.S. revenues were (1)% in the period, reflecting the changed seasonality of the U.S. business since the Quest transaction.
Europe & Rest of World, or ROW, revenue was $2.7 million in the third quarter of 2019, up 19% when compared to the third quarter of 2018. On a constant currency basis, Europe & ROW revenue increased 24% versus the third quarter 2018. The higher revenue in the third quarter of 2019 reflected continued strong growth in both Russia and our U.K. service laboratory.
Asia revenue was $12.8 million in the third quarter of 2019, representing an increase of 17% compared to third quarter 2018 revenue of $10.9 million. On a constant currency basis, Asia revenue increased 15% versus the third quarter of 2018, primarily driven by growth in Japan.
Gross profit for the third quarter of 2019 was $15.5 million, an increase of $4.0 million from gross profit of $11.5 million in the same period of 2018. Gross margin was 73.0%, an increase of 150 basis points from gross margin of 71.5% in the third quarter of 2018 and up sequentially 60 basis points versus the second quarter of 2019.
Operating expenses were $15.4 million in the third quarter of 2019, a decrease of $1.1 million compared to $16.5 million in the third quarter of 2018.
Net income for the third quarter of 2019 was $0.7 million, or $0.03 per share on both a basic and diluted basis, compared to a net loss of $(3.5) million, or $(0.13) per share on both a basic and diluted basis, in the third quarter of 2018. Basic net income/(loss) per share was based on 26,751,083 and 26,033,550 weighted average ordinary shares outstanding for the third quarters of 2019 and 2018, respectively. Diluted net income/(loss) per share was based on 26,936,541 and 26,033,550 weighted average ordinary shares outstanding for the third quarters of 2019 and 2018, respectively.
EBITDA for the third quarter of 2019 was $956,000 compared to $(4.8) million in the third quarter of 2018. Adjusted EBITDA was $1.9 million for the third quarter of 2019 compared to $(1.4) million in the same period in 2018. Both EBITDA and Adjusted EBITDA are non-GAAP measures.
For full year 2019, the Company now expects revenues of between $72 and $73 million. The Company expects revenues of between $16.4 and $17.4 million in the fourth quarter.
Oxford Immunotec will host a conference call on Tuesday, Novermber 5, 2019 at 8:00 a.m. Eastern Standard Time to discuss its third quarter 2019 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 7098484 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec’s website at www.oxfordimmunotec.com. The replay will be available on the Company’s website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease. The Company’s T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company is headquartered near Oxford, United Kingdom and in Marlborough, Massachusetts. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT, the Oxford Immunotec logo, ODL, and the Oxford Diagnostic Laboratories logo are trademarks of Oxford Immunotec Limited. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this release are forward-looking statements. This includes statements about Oxford Immunotec’s anticipated plans and objectives, future performance and revenues, financial condition, prospects for sales of its products, growth, strategies, expectations and objectives of management. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements contained in this release reflect Oxford Immunotec’s current expectations and are subject to risks and uncertainties. Actual results may differ materially from those projected or implied by forward-looking statements. Other factors that could adversely affect Oxford Immunotec’s business and prospects are described under the “Risk Factors” section in its filings with the Securities and Exchange Commission (“SEC”). Oxford Immunotec’s SEC filings are available for free by visiting the investor section of its website, www.oxfordimmunotec.com, or the SEC’s website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. Investors should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. Oxford Immunotec does not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For detailed financial information, please click here.